Huifang Xie

Huifang Xie


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
ALAiqun Lin
Aiqun Lin
WZWenxia Zheng
Wenxia Zheng
YHYan He
Yan He
WTWenli Tang
Wenli Tang
XWXiaobo Wei
Xiaobo Wei
HXHuifang Xie
Huifang Xie

1 July 2020 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
WZWenxia Zheng
Wenxia Zheng
RHRongni He
Rongni He
ZYZhenxing Yan
Zhenxing Yan
YHYaowei Huang
Yaowei Huang
WHWei Huang
Wei Huang
HXHuifang Xie
Huifang Xie

1 June 2018 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
RHRongni He
Rongni He
WHWei Huang
Wei Huang
YHYaowei Huang
Yaowei Huang
MXMiaojing Xu
Miaojing Xu
PSPingping Song
Pingping Song
YHYafang Hu
Yafang Hu
Parkinson’s disease (PD) is one of the most affected neurodegenerative diseases in the world. Deregulation of cyclin-dependent kinase 5 (Cdk5) is believed to play an important role in neurodegenerative diseases including PD. p25 is a cleavage peptide of p35, a physiologic activator of Cdk5. p25 combines to Cdk5 and leads to the hyperactivity of Cdk5, which in turn hyperphosphorylates downstream substrates and leads to neuroinflammation and apoptosis of neurons. Previously, we have demonstrated that adeno-associated virus serotype-9 (AAV9) mediated Cdk5 inhibitory peptide (CIP) inhibits the activity of Cdk5/p25 complex and alleviates pathologic and behavioral changes in Alzheimer’s disease mouse model. In this study, we evaluated whether AAV9-CIP protected dopaminergic (DA) neurons in 1-methyl-4-phe-nyl-1,2,3,6-tetrahydropyridine-probenecid (MPTP/p) induced PD mouse model. The data showed that administration of AAV9-CIP by intracerebroventricular injection 1 week before MPTP/p exposure protected loss of DA neurons in substantia nigra compact of the model mice. Importantly, AAV9-CIP also alleviated the motor and anxiety-like symptoms of the disease animals. In summary, AAV9 mediated CIP might be a potential intervention for PD.

1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
YZYang Zou
Yang Zou
YHYaowei Huang
Yaowei Huang
SLSiqin Liu
Siqin Liu
JYJuan Yang
Juan Yang
WZWenxia Zheng
Wenxia Zheng
HXHuifang Xie
Huifang Xie
Atherosclerosis is a chronic inflammatory disease with a high prevalence worldwide, contributing to a series of adverse cardiovascular and cerebrovascular diseases. Periodontal disease induced by pathogenic periodontal microbiota has been well established as an independent factor of atherosclerosis. Periodontal microorganisms have been detected in atherosclerotic plaques. The high‐risk microbiota dwelling in the subgingival pocket can stimulate local and systematic host immune responses and inflammatory cascade reactions through various signaling pathways, resulting in the development and progression of atherosclerosis. One often‐discussed pathway is the Toll‐like receptor‐nuclear factor‐κB (TLR‐NF‐κB) signaling pathway that plays a central role in the transduction of inflammatory mediators and the release of proinflammatory cytokines. This narrative review is aimed at summarizing and updating the latest literature on the association between periodontopathic microbiota and atherosclerosis and providing possible therapeutic ideas for clinicians regarding atherosclerosis prevention and treatment.

1 August 2019 in Life Sciences
Verified
Journal Article
Closed access
YSYu-Ying Su
Yu-Ying Su
HLHuan-Min Li
Huan-Min Li
ZYZhen-Xing Yan
Zhen-Xing Yan
MLmingchun Li
mingchun Li
JWJi-Peng Wei
Ji-Peng Wei
CLChun-Guang Li
Chun-Guang Li

20 October 2018 in BMC Neurology
Verified
Journal Article
Open access
PDF file
WZWenxia Zheng
Wenxia Zheng
ZYZhenxing Yan
Zhenxing Yan
RHRongni He
Rongni He
YHYaowei Huang
Yaowei Huang
ALAiqun Lin
Aiqun Lin
HXHuifang Xie
Huifang Xie
DNA methyltransferase 1 (EC 2.1.1.37), encoded by DNMT1 gene, is one of key enzymes in maintaining DNA methylation patterns of the human genome. It plays a crucial role in embryonic development, imprinting and genome stability, cell differentiation. The dysfunction of this group of enzymes can lead to a variety of human genetic disorders. Until now, mutations in DNMT1 have been found to be associated with two distinct phenotypes. Mutations in exon 20 of this gene leads to hereditary sensory and autonomic neuropathy type IE, and mutations in exon 21 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. Here we report a novel DNMT1 mutation in a sporadic case of a Chinese patient with cerebellar ataxia, multiple motor and sensory neuropathy, hearing loss and psychiatric manifestations. Furthermore, we elucidated its pathogenic effect through molecular genetics studies and revealed that this defective DNMT1 function is responsible for the phenotypes in this individual. Our findings expand the spectrum of DNMT1-related disorders and provide a good example of precision medicine through the combination of exome sequencing and clinical testing.